Bio­gen's Alzheimer's drug ad­u­canum­ab im­plodes in a PhI­II dis­as­ter — putting them at a per­ilous cross­roads

7 years ago
R&D

Faster, cheap­er, bet­ter? Post-buy­out deal Cel­gene jumps in­to AI al­liance with a $25 mil­lion bet on speed­ing dis­cov­ery ...

7 years ago
AI

NASH drug in hand, Mer­ck forges ahead with 2-year ex­ten­sion of NGM Bio col­lab­o­ra­tion deal

7 years ago
R&D
Pharma

To tack­le soar­ing pre­scrip­tion drug costs, Cana­da cre­ates new agency to ne­go­ti­ate prices; DMC clears phI­II test­ing of ...

7 years ago
News Briefing

EMA sounds its own safe­ty alarm for Pfiz­er block­buster, but they’re al­so not forc­ing a lim­it on dos­ing — yet

7 years ago
Pharma

With eye on rev­enue sta­bi­liza­tion, Gilead takes 4.9% hike on a bas­ket of drugs

7 years ago
Pharma

Flag­ship ties up a mon­ster $824M fund to back a new wave of biotech star­tups seed­ed in their lab

7 years ago
Financing

Pfiz­er lines up a po­ten­tial $687M rare dis­ease buy­out to ex­pand its stake in the hot gene ther­a­py field

7 years ago
Pharma
Cell/Gene Tx

Glax­o­SmithK­line sets its sights on a quick leap in­to the big PD-1/L1 game — will any­one no­tice?

7 years ago
R&D

Fol­low­ing Syn­tim­mune buy­out, Alex­ion antes up $25M to dou­ble down on an­ti-FcRn path­way

7 years ago
Pharma

Pfiz­er, Mer­ck KGaA throw in the tow­el on an­oth­er Baven­cio PhI­II as once bright hopes shriv­el fast

7 years ago
R&D

FDA ap­proves trail­blaz­ing post­par­tum de­pres­sion ther­a­py, in cru­cial mile­stone for wom­en's health

7 years ago
Pharma

Seek­ing a place among gi­ants in the on­colyt­ic virus field, lit­tle Cold Genesys bags $22M Se­ries C

7 years ago
Financing

Skin re­gen­er­a­tion com­pa­ny Po­lar­i­tyTE re­veals SEC in­ves­ti­ga­tion, prob­ing in­to its lead prod­uct, for­mer CFO and cur­rent ...

7 years ago
Pharma

Af­fimed lands mile­stone from Roche; Puma touts new PHII da­ta on cer­vi­cal can­cer

7 years ago
News Briefing

Bris­tol-My­ers and Star­board Val­ue spar over $74B Cel­gene buy­out as share­hold­er vote looms

7 years ago
Deals

Roche, Ab­b­Vie forced to slam brakes on myelo­ma stud­ies of star drug Ven­clex­ta af­ter re­searchers flag high­er risk of ...

7 years ago
R&D

Vivek Ra­maswamy’s Urovant claims a big win in PhI­II — but ques­tions linger about a cheap gener­ic and their ...

7 years ago
R&D

Roche stacks up Tecen­triq nods, fol­low­ing up breast can­cer ap­proval with small cell lung can­cer

7 years ago
Pharma

Is a new CEO in the cards at Sanofi as suc­ces­sion plan­ning heats up for top team?

7 years ago
People

Part­ner­ing talks led to Bio­gen’s $800M Night­star buy­out as play­ers clus­tered around the hot deal ta­ble for gene ...

7 years ago
Deals

Aim­mune wins 12-month re­view and ad­com for peanut al­ler­gy drug; Phase­Bio flies on ear­ly da­ta for Bril­in­ta re­ver­sal ...

7 years ago
News Briefing

Amarin posts an­oth­er round of promis­ing car­dio out­comes da­ta for Vas­cepa. Cue more M&A chat­ter and ar­gu­ment

7 years ago
R&D

Al­ler­gy Ther­a­peu­tic­s' im­munother­a­py prospect tar­nished af­ter birch vac­cine flops in PhI­II

7 years ago
R&D
First page Previous page 950951952953954955956 Next page Last page
A service from the Financial Times